Healthcare / Diagnostics & ResearchSão Paulo
$3.41
-0.14 (-3.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $10.8M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$519M
P/E
N/A
•EV/EBITDA
6.7x
↓ROE
-11.8%
↓Gross Margin
29.2%
↓Debt/Equity
0.87
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+2.3%
FCF CAGR
—
FCF margin
-11.5%
FCF / Net income
1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.22B · net income $-129.1M · FCF $-140.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.22B | $1.22B | $1.18B | $1.09B | $1.14B |
| Net Income | $-129.1M | $-129.1M | $-227.9M | $-227.8M | $-5.6M |
| EBITDA | $184.7M | $184.7M | $96.5M | $74.6M | $206.4M |
| EPS | -1.09 | -1.09 | -1.93 | -1.93 | -0.05 |
| Gross Margin | 29.2% | 29.2% | 30.9% | 30.0% | 31.3% |
| Operating Margin | 9.3% | 9.3% | 2.8% | -4.0% | 7.2% |
| Net Margin | -10.6% | -10.6% | -19.3% | -21.0% | -0.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.87 | 0.87 | 1.43 | 1.41 | 0.91 |
| Current Ratio | 1.00 | 1.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-140.4M | $-140.4M | $10.8M | $74.3M | $48.6M |
| Returns | |||||
| ROE | -11.8% | -11.8% | -24.8% | -24.0% | -0.5% |
| Valuation | |||||
| EV/EBITDA | 6.71 | 6.71 | 22.18 | 48.57 | 11.89 |
| P/B | 0.37 | 0.37 | 1.14 | 2.64 | 1.29 |
| Growth & Yield | |||||
| Revenue Growth | 3.2% | 3.2% | 8.7% | -4.5% | — |
| EPS Growth | 43.3% | 43.3% | 0.4% | -3941.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-43.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.93 → -1.09
Residual
-43.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.